8-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 24, 2007

SurModics, Inc.

(Exact name of Registrant as Specified in its Charter)

Minnesota
(State or Other Jurisdiction of Incorporation)

0-23837
(Commission File Number) 41-1356149
(IRS Employer
Identification No.)

9924 West 74^th Street
Eden Prairie, Minnesota 55344
(Address of Principal Executive Offices and Zip Code)

(952) 829-2700
(Registrant’s telephone number, including area code)

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

TABLE OF CONTENTS

	Item 2.02 Results of Operations and Financial Condition.
	Item 9.01 Financial Statements and Exhibits.
Signatures
Exhibit Index
Press Release

Item 2.02 Results of Operations and Financial Condition.

     On January 24, 2007, SurModics, Inc. issued a press release announcing the results for the quarter ended December 31, 2006. The copy of the full text of the press release is furnished as Exhibit 99.1 to this report.

Item 9.01 Financial Statements and Exhibits.

(a)	Financial Statements: None.
(b)	Pro forma financial information: None
(c)	Shell company transactions: None
(d)	Exhibits: 99.1 Press Release dated January 24, 2007.

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	SURMODICS, INC.
	By	/s/ Philip D. Ankeny
Date: January 24, 2007		Name:	Philip D. Ankeny
		Title:	Chief Financial Officer

SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

EXHIBIT INDEX
to
FORM 8-K

SURMODICS, INC.

Date of Report:	Commission File No.:
January 24, 2007	0-23837

Exhibit No.	ITEM
99.1	Press Release dated January 24, 2007.

EX-99.1

Exhibit 99.1

FOR IMMEDIATE RELEASE

SurModics Reports First Quarter 2007 Results
23% Growth in Non-CYPHER Revenue

EDEN PRAIRIE, Minnesota — January 24, 2007 — SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, today reported financial results for the first quarter ended December 31, 2006.

First Quarter Highlights (GAAP):

• Revenue of $16.7 million, up 2% year-over-year

• Operating income of $8.1 million; operating margin of 48%

• Net income of $6.0 million

• Diluted EPS of $0.32

• Operating cash flow of $11.8 million

• Non-CYPHER-related revenue increased 23% year-over-year

• Two new licenses signed with SurModics customers

• Four new customer products introduced

• Completed the repurchase of $17.5 million of common stock

“SurModics is pleased to report 23% growth in non-CYPHER revenue for the first quarter of fiscal year 2007,” said Bruce Barclay, President and CEO. “Our overall performance during the period was negatively impacted by reduced penetration in the drug eluting stent market resulting from the controversy around late stent thrombosis, and as we had expected, lower R&D revenue compared to historical levels. However, we remain pleased with the progress we are making on our strategic plan for sustainable growth, and are confident in our ability to achieve our long-term goals.”

“SurModics continues to experience strong customer interest in our ophthalmology technologies, and we are making significant progress in driving these projects forward,” continued Barclay. “While R&D revenue was $0.8 million in the quarter, down from

$1.8 million a year ago, we have recently signed new R&D agreements with various ophthalmology customers totaling more than $2.5 million, with more R&D agreements expected based on current negotiations. Based on these new and expected agreements and meaningful progress on other customer projects across the business, we expect R&D revenue for all of fiscal 2007 to approximate or possibly even exceed last year’s near-record R&D revenue of $5.7 million.”

“Additionally, we continue to have encouraging customer interest in our prohealing and drug delivery polymer technologies,” continued Barclay. “Our In Vitro Technologies business had a particularly robust quarter, and our Hydrophilic Technologies business continues to do well.”

Revenue for the first quarter of fiscal 2007 was $16.7 million, an increase of 2% from $16.5 million in the year earlier period. Operating income was $8.1 million, a 5% decrease from $8.6 million in the prior year period. Net income was $6.0 million, a 4% decrease from $6.2 million in the same period last year. Diluted earnings per share was $0.32, compared with $0.33 in the first quarter of fiscal 2006. Prior year results include a $465,000, or $0.02 per diluted share, benefit related to the reversal of a tax reserve; there was no such benefit in the first quarter of fiscal 2007.

SurModics’ pipeline continues to represent significant potential. The company signed two new licenses in the first quarter, with many more potential licenses currently in negotiation. The company has a goal of 18 new licenses for fiscal year 2007, and we remain confident in our ability to achieve that objective. Our customers launched four new products in the marketplace during the quarter, bringing to 14 the number of launches achieved toward our goal of 30 launches between April 2006 and September 2007. As of December 31, 2006, SurModics’ customers had 89 licensed product classes generating royalty revenue, up from 80 in the prior-year period; the total number of licensed product classes not yet launched was 80, compared with 74 in the prior-year period; and major non-licensed opportunities totaled 80, compared with 67 a year ago. In total, SurModics now has 160 potential commercial products in development representing each of the company’s four focus markets — Cardiovascular, Ophthalmology, Orthopedics and Neurology.

SurModics’ cash and investment balance was $99.6 million as of December 31, 2006, and we have no debt. Operating cash flow for the quarter was $11.8 million, a 14% increase from $10.4 million in the prior year period. “SurModics remains in excellent financial condition,” said Phil Ankeny, Senior Vice President and Chief Financial Officer. “We were pleased to complete the repurchase of $17.5 million of stock during the quarter under the $35 million share repurchase program authorized by our Board in September. We continue to manage our expenses responsibly, without compromising our investment in R&D. Furthermore, our business development pipeline continues to grow, as we evaluate potentially compelling opportunities to grow our business and put our balance sheet to work.”

Live Webcast

SurModics will host a webcast at 5:00 p.m. ET (4:00 p.m. CT) today to discuss the quarterly results. To access the webcast, go to the investor relations portion of the company’s web site, www.surmodics.com, and click on the first quarter webcast icon. A replay of the first quarter conference call will be available by dialing 800-405-2236 and entering conference call ID 11081575. The audio replay will be available beginning at 7:00 p.m. CT on Wednesday, January 24, until 7:00 p.m. CT on Wednesday, January 31.

About SurModics, Inc.

SurModics, Inc. is a leading provider of surface modification technologies in the areas of biocompatibility, site specific drug delivery, biological cell encapsulation, and medical diagnostics. SurModics partners with the world’s foremost medical device, pharmaceutical and life science companies to bring innovation together for better patient outcomes. Recent collaborative efforts include the implementation of SurModics’ Bravo™ drug delivery polymer matrix as a key component of the first-to-market drug-eluting coronary stent. SurModics is also active in the ophthalmology market with a sustained drug delivery system that is currently in human trials for treatment of retinal disease. A significant portion of SurModics’ revenue is generated by royalties earned from the sale of our customers’ commercial products. SurModics is headquartered in Eden Prairie, MN. More information about the company can be found at www.surmodics.com. The content of SurModics’ web site is not part of this release or part of any filings the company makes with the SEC.

Safe Harbor for Forward Looking Statements

Certain statements contained in this press release may be deemed to be forward-looking statements under federal securities laws, and SurModics intends that such forward looking statements be subject to the safe harbor created thereby. SurModics does not undertake an obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact

Phil Ankeny, Senior Vice President and Chief Financial Officer
(952) 829-2700

SurModics, Inc.
Statements of Income
(In thousands, except per share data)

	Three Months Ended
	December 31,
	2006			2005
	(Unaudited)
Revenue:
Royalties and license fees	$	13,219		$	12,275
Product sales		2,726			2,347
Research & development		795			1,843
Total revenue		16,740			16,465
Operating expenses:
Product		1,086			681
Research & development		5,207			4,593
Sales & marketing		311			324
General & administrative		2,027			2,287
Total operating expenses		8,631			7,885
Income from operations		8,109			8,580
Investment income		1,329			728
Income before income taxes		9,438			9,308
Income tax provision		(3,446	)		(3,090	)
Net income	$	5,992		$	6,218
Basic net income per share	$	0.32		$	0.34
Diluted net income per share	$	0.32		$	0.33
Weighted average shares outstanding
Basic		18,456			18,436
Diluted		18,556			18,643

-more-

SurModics, Inc.
Condensed Balance Sheets
(In thousands)

	December 31,		September 30,
	2006		2006
	(Unaudited)
Assets
Current assets:
Cash & investments	$	50,375	$	58,813
Accounts receivable		12,537		14,493
Inventories		933		952
Other current assets		1,992		1,838
Total current assets		65,837		76,096
Property & equipment, net		11,446		11,686
Long-term investments		49,243		47,758
Other assets		25,204		21,862
Total assets	$	151,730	$	157,402
Liabilities & Stockholders’ Equity
Total current liabilities	$	10,052	$	8,989
Other liabilities		3,357		3,210
Total stockholders’ equity		138,321		145,203
Total liabilities & stockholders’ equity	$	151,730	$	157,402

-more-

SurModics, Inc.
Condensed Statements of Cash Flows
(In thousands)

	Three months ended
	December 31,
	2006			2005
	(Unaudited)
Operating Activities
Net Income	$	5,992		$	6,218
Depreciation and amortization		986			878
Net other operating activities		878			982
Net change in operating assets and liabilities		3,924			2,277
Net cash provided by operating activities		11,780			10,355
Investing Activities
Net purchases of property and equipment		(1,226	)		(2,823	)
Net other investing activities		2,016			(10,051	)
Net cash provided (used) by investing activities		790			(12,874	)
Financing Activities
Issuance of common stock		1,428			359
Repurchase of common stock		(17,516	)		—
Net other financing activities		—			43
Net cash provided (used) by financing activities		(16,088	)		402
Net change in cash and cash equivalents		(3,518	)		(2,117	)
Cash and Cash Equivalents
Beginning of period		3,751			3,921
End of period	$	233		$	1,804

# # #